Amgen and Allergan Report Submission of BLA to the US FDA for its ABP 798 (biosimilar, rituximab)

 Amgen and Allergan Report Submission of BLA to the US FDA for its ABP 798 (biosimilar, rituximab)

Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

Shots:

  • The BLA submission is based on two studies assessing ABP 798 vs Rituxan which resulted in analytical, PK and clinical data showing no clinically meaningful differences between products
  • In Dec, 2011 Amgen and Allergan globally collaborated to develop and commercialize four oncology antibody biosimilar medicines
  • ABP 798 is a mAb CD20-directed cytolytic mAb approved for RA, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) in the US and EU. Additionally, Amgen has 10 biosimilars in its portfolio four approved in the US and three in EU

Click here to read full press release/ article | Ref: Amgen | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post